ILMN Dec 2024 180.000 call
| Previous close | 5.95 |
| Open | 5.95 |
| Bid | 2.30 |
| Ask | 9.50 |
| Strike | 180.00 |
| Expiry date | 2024-12-20 |
| Day's range | 5.95 - 5.95 |
| Contract range | N/A |
| Volume | |
| Open interest | 45 |
ReutersIllumina reaffirms annual revenue forecast over continued sluggish demand
The San Diego, California-based company, whose tools and services are used in developing therapies and vaccines, has seen both a slowdown in demand from key markets such as China and cautious spending from its customers. The gene sequencing machine maker continues to expect revenue growth from its core segment to be roughly flat this year compared with 2023, and still sees its adjusted operating margin to be about 20%. U.S. life sciences Illumina's first-quarter revenue was $1.08 billion, above analysts' estimate of $1.05 billion.
GuruFocus.comIllumina Inc (ILMN) Q1 Earnings: Navigating Through Challenges with Mixed Results
Comparative Analysis of Q1 2024 Financial Performance Against Analyst Expectations
PR NewswireIllumina Reports Financial Results for First Quarter of Fiscal Year 2024
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2024, which include the consolidated financial results for GRAIL.
